Investigation of the biologic activity of Insulin-like Growth Factor I/Somatomedin C (IGF-I/Sm C) has been hampered by the scarcity of purified material. The synthesis of this molecule by the solid phase procedure and an analog of IGF-I/Sm C by recombinant DNA technology offers promise that studies of the biologic activity of IGF-I/Sm C will soon be possible. We have found that natural IGF-I/Sm C and the two synthetic peptides behave similarly in two radioligand systems, providing evidence that these molecules possess the requisite structural integrity for use in such biological studies.